Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Kyowa Kirin Co., Ltd.
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03970798CT.gov A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin | — | Completed | — | — | — |
NCT01190735CT.gov Caffeine for Motor Manifestations of Parkinson's Disease | — | Completed | — | — | — |
NCT00459420CT.gov Caffeine for Excessive Daytime Somnolence in Parkinson's Disease | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Parkinson Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Caffeine (this asset) | Kyowa Kirin Co., Ltd. | P3 | BB · 67 |
| Safinamide | Zambon SpA | P4 | A |
| Rasagiline | Guangzhou Henovcom Bioscience Co. Ltd. | P4 | BBB |
| Istradefylline | Georgetown University | P4 | BBB |
| Opicapone | Bial - Portela C S.A. | P4 | BBB |
| Ropinirole | Titan Pharmaceuticals | P4 | BBB |
| Cvt-301 | Acorda Therapeutics | P3 | BBB |
| Pardoprunox | Abbott Products | P3 | BBB |
| Carbidopa | Tanta University | P4 | BBB |
+42 more in the Parkinson Disease cohort
Other indications for Caffeine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Migraine Disorder | — | P4 | BBB · 72 |
| Renal Cell Carcinoma | — | P4 | B · 63 |
| Non-Small Cell Lung Carcinoma | — | P4 | B · 63 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Caffeine in Parkinson Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/caffeine-parkinson-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →